-+ 0.00%
-+ 0.00%
-+ 0.00%
Transcenta licenses HiCB bioprocessing technology to WuXi Biologics for RMB 10 million upfront
Share
Listen to the news
Transcenta licenses HiCB bioprocessing technology to WuXi Biologics for RMB 10 million upfront
  • Transcenta entered a technology licensing and strategic collaboration agreement with WuXi Biologics covering its HiCB bioprocessing platform.
  • WuXi received a non-exclusive license to HiCB-related technologies and ExcelPro cell culture media for commercialization.
  • Upfront payment set at RMB 10 million, with additional milestone payments tied to specified conditions.
  • WuXi will act as Transcenta’s strategic partner for CMC development across its pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN43555) on September 09, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending